Georgia Xourafa
Welcome,         Profile    Billing    Logout  
 10 Trials 
2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Roden, Michael
COMBAT_T2_NASH, NCT04639414 / 2019-001987-31: Combined Active Treatment in Type 2 Diabetes with NASH

Active, not recruiting
4
192
Europe
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo
German Diabetes Center, Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S
Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
01/25
12/25
NCT05160272: Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes

Completed
2
38
Europe
AP-325, Placebo matching AP-325
The Deutsche Diabetes Forschungsgesellschaft e.V., Algiax Pharmaceuticals GmbH
Type2 Diabetes
12/24
12/24
Xourafa, Georgia
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Roden, Michael
COMBAT_T2_NASH, NCT04639414 / 2019-001987-31: Combined Active Treatment in Type 2 Diabetes with NASH

Active, not recruiting
4
192
Europe
Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo
German Diabetes Center, Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S
Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD)
01/25
12/25
NCT05160272: Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes

Completed
2
38
Europe
AP-325, Placebo matching AP-325
The Deutsche Diabetes Forschungsgesellschaft e.V., Algiax Pharmaceuticals GmbH
Type2 Diabetes
12/24
12/24
Xourafa, Georgia
No trials found

Download Options